Shift in Balance of IV Iron-to-Epoetin USE: 2008-2011
Recent post hoc analyses of large randomized clinical trials have suggested an association between high ESA dose and cardiovascular events (Szczech et al. 2008 KI 74:791). In 2011, implementation of CMS ESRD bundled payment and FDA-mandated ESA label changes that target lower hemoglobin (Hb) created...
Main Authors: | Alex Yang, Ali Hariri, Will Harrison, Jay Wish |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society of Nephrology
2012-06-01
|
Series: | Kidney Research and Clinical Practice |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211913212006614 |
Similar Items
-
DOSE ADJUSTMENT PRACTICES OF PEGINESATIDE VS. EPOETIN IN EMERALD 1 AND 2 PIVOTAL TRIALS
by: Amit Sharma, et al.
Published: (2012-06-01) -
The Use of Epoetin-α in Revision Knee Arthroplasty
by: Lawrence A. Delasotta, et al.
Published: (2012-01-01) -
Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies
by: Jay B. Wish, et al.
Published: (2019-09-01) -
Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
by: Steven Fishbane, et al.
Published: (2019-09-01) -
Epoetin Alpha and Epoetin Zeta: A Comparative Study on Stimulation of Angiogenesis and Wound Repair in an Experimental Model of Burn Injury
by: Natasha Irrera, et al.
Published: (2015-01-01)